Scarica l'app Stockscreener
0.4024
53.61%
-0.4651
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché VCNX Giù?
Forum
Previsione
Frazionamento azionario
Vaccinex Inc Borsa (VCNX) Ultime notizie
Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World
Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
What sets apart Novavax option from other COVID-19 vaccines - American Medical Association
Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
Senators from both parties grilled RFK Jr. on vaccines and more - NPR
Vaccine Development - Gates Foundation
TR | OpenAI4o Maintains Vaccinex(VCNX.US) With Hold Rating, Cuts Target Price to $0.5 - 富途牛牛
Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World
Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World
Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India
Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus
Vaccinex presents promising cancer treatment data at ASCO - Investing.com
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan
Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire
Vaccinex reports pepinemab boosts immune response in cancer - Investing.com
Vaccinex director resigns, no disagreement cited - Investing.com
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - Yahoo Finance
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
VCNX Stock Price and Chart — OTC:VCNX - TradingView
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards - Quiver Quantitative
School Vaccine Mandates - Britannica
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com UK
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Stocktwits
Vaccinex exercises warrants for proceeds of $6.2M - Seeking Alpha
Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns - TipRanks
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges - ACS Publications
Vaccinex says Alzheimer's candidate buoyed by additional early-stage data (NASDAQ:VCNX) - Seeking Alpha
VBI Vaccines to be delisted from Nasdaq following restructuring - Investing.com
Alzheimer’s drug development roundup – July 2024 - European Pharmaceutical Review
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease - Stock Titan
Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market | DelveInsight - PR Newswire
Vaccinex Announces Pricing of $3.7 Million PIPE Financing - GlobeNewswire
Vaccinex Completes Key Study Phase for Alzheimer’s Drug - TipRanks
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease - Yahoo Finance
FCMI parent co. purchases $9.2k worth of Vaccinex shares - Investing.com
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Eight monoclonal antibody biotechs making strides in the clinic - Labiotech.eu
What's Driving These Stocks Higher In After-hours? - RTTNews
(VCNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Vaccinex faces Nasdaq compliance challenge By Investing.com - Investing.com Canada
Vaccinex Reports 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Vaccinex prices 193,000 shares at $7.77 in registered direct offering - TipRanks
0.01%
0.53%
Capitalizzazione:
|
Volume (24 ore):